Skip to main content
PepStack
Wiki · Profile

Cerebrolysin

FPF-1070

Nootropic & CNSApproved
From$0.63/mgCompare prices

Cerebrolysin is a neuropeptide preparation derived from porcine brain tissue, consisting of low-molecular-weight peptides and amino acids. Researchers primarily study it for its potential neuroprotective and neurotrophic properties, particularly in the context of neurological disorders such as acute ischaemic stroke and neurodegenerative diseases. Key findings from clinical studies suggest that while Cerebrolysin may not significantly reduce all-cause mortality or serious adverse events in acute ischaemic stroke, it has been associated with an increase in non-fatal serious adverse events. Current research continues to explore its efficacy and safety, with ongoing investigations into its mechanisms of action and potential applications in various neurological conditions.

Chemical Profile

Chemical Profile

Half-Life

INIntranasal

Not applicable

POOral

Poor bioavailability

Pharmacokinetic data is limited, with rapid distribution and elimination observed.

Mechanism

Mechanism of Action

Cerebrolysin, a mixture of low-molecular-weight peptides and amino acids derived from porcine brain, exerts its neuroprotective effects potentially through the activation of neurotrophic receptors such as the TrkB receptor, which is involved in the Brain-Derived Neurotrophic Factor (BDNF) signaling pathway. This activation may enhance neuronal survival, promote neurogenesis, and modulate synaptic plasticity, although the precise molecular mechanisms and all involved signaling pathways remain not fully understood. Additionally, Cerebrolysin may influence the NO/cGMP pathway, contributing to neuroprotection and anti-inflammatory effects in the context of neurological disorders.

Research

71 Research Publications

1,523

Total Citations

8

Human/RCT

1.7

Avg. Influence

2025

Latest

Sort
Filter
#01

Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke.

AnimalInfluence2.0
137
Researchers observed that Cerebrolysin enhances neurogenesis and improves neurological function after stroke in rats, mediated by the Sonic hedgehog signaling pathway.
10 and 30 mL(human)2.5 ml/kgintraperitoneal(rat)10 consecutive days2.5 mL/kg per dayi.p.(mouse)
PubMed
#02

The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders.

ReviewInfluence5.0
124
The review highlighted that cerebrolysin mimics neurotrophic factors, promoting brain protection and repair in various neurological disorders.
10 and 30 mL(human)2.5 ml/kgintraperitoneal(rat)10 consecutive days2.5 mL/kg per dayi.p.(mouse)
PubMed
#03

Cerebrolysin for vascular dementia.

Chen Ning, et al. · The Cochrane database of systematic reviews · 2013

Meta-AnalysisInfluence2.0
101
Researchers studied the effects of Cerebrolysin on cognitive function in elderly patients with vascular dementia. They found that Cerebrolysin may improve general cognitive abilities and overall clinical function, although the evidence is not strong enough to recommend it as a standard treatment.

Key findings

  1. 01Cerebrolysin showed a beneficial effect on cognitive function as measured by standard assessments.
  2. 02The treatment also improved global clinical function in participants.
  3. 03Only non-serious side effects were reported, with no significant difference in side effects between treatment and control groups.
PubMed
#04

Cerebrolysin: a review of its use in dementia.

HumanInfluence1.0
78
The study demonstrated that cerebrolysin improved cognitive outcomes in patients with Alzheimer's disease compared to placebo, suggesting its potential as a treatment option for dementia.
PubMed
#05

Cerebrolysin for acute ischaemic stroke.

Ziganshina Liliya Eugenevna, et al. · The Cochrane database of systematic reviews · 2020

Human
69
The study demonstrated that moderate-quality evidence indicates Cerebrolysin probably has little or no beneficial effect on preventing all-cause death in acute ischaemic stroke.

Key findings

  1. 01Cerebrolysin probably results in little to no difference in all-cause death rates among stroke patients.
  2. 02There is likely no significant difference in the total number of serious adverse events between those treated with Cerebrolysin and those given a placebo.
  3. 03The study suggests a potential increase in non-fatal serious adverse events associated with Cerebrolysin use.
PubMed
#06

Neurotrophic activities and therapeutic experience with a brain derived peptide preparation.

HumanInfluence1.0
68
Researchers observed that cerebrolysin exhibited neurotrophic and neuroprotective properties in various neuronal models, leading to improvements in cognitive performance in Alzheimer's patients with long-lasting effects after treatment cessation.
10 and 30 mL(human)2.5 ml/kgintraperitoneal(rat)10 consecutive days2.5 mL/kg per dayi.p.(mouse)
PubMed
#07

Neuroprotective effects of cerebrolysin, a combination of different active fragments of neurotrophic factors and peptides on the whole body hyperthermia-induced neurotoxicity: modulatory roles of co-morbidity factors and nanoparticle intoxication.

AnimalInfluence1.0
57
Researchers observed that Cerebrolysin administration significantly reduced blood-brain barrier disruption and neurotoxicity in a rat model subjected to whole body hyperthermia.
10 and 30 mL(human)2.5 ml/kgintraperitoneal(rat)10 consecutive days2.5 mL/kg per dayi.p.(mouse)
PubMed
#08

Cerebrolysin reduces amyloid-β deposits, apoptosis and autophagy in the thalamus and improves functional recovery after cortical infarction.

AnimalInfluence2.0
55
Researchers observed that Cerebrolysin reduced amyloid-β deposits and neuronal apoptosis in the thalamus, leading to improved functional recovery after cortical infarction in rats.
10 and 30 mL(human)2.5 ml/kgintraperitoneal(rat)10 consecutive days2.5 mL/kg per dayi.p.(mouse)
PubMed
#09

Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.

HumanInfluence1.0
46
The study demonstrated that Cerebrolysin improves cognitive, global, and functional domains in patients with Alzheimer's disease and vascular dementia, with effects persisting for several months.
10 and 30 mL(human)2.5 ml/kgintraperitoneal(rat)10 consecutive days2.5 mL/kg per dayi.p.(mouse)
PubMed
#10

Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks.

Satou T, et al. · Journal of neural transmission (Vienna, Austria : 1996) · 2000

In VitroInfluence2.0
45
Researchers studied the effects of FPF-1070 (Cerebrolysin) on nerve growth in chicken embryo neurons. They found that FPF-1070 promoted nerve growth in certain types of neurons but was less effective than nerve growth factor. The study also revealed that FPF-1070 had no impact on another type of neuron, indicating its effects vary by neuron type.

Key findings

  1. 01FPF-1070 significantly promoted neurite outgrowth in dorsal root ganglia and sympathetic trunk neurons.
  2. 02The effectiveness of FPF-1070 showed an inverted U relationship with concentration in these neurons.
  3. 03FPF-1070 did not affect neurite outgrowth in ciliary ganglia neurons, which responded well to another growth factor.
PubMed
Safety

Safety & Handling

Research Gaps

There is a lack of comprehensive long-term human trials assessing the efficacy and safety of Cerebrolysin, particularly regarding its impact on functional outcomes and quality of life post-treatment. Additionally, the precise mechanisms by which Cerebrolysin exerts its neuroprotective effects remain unclear, especially in the context of its interaction with amyloid beta and phosphorylated tau in neurodegenerative conditions.

Solubility

Cerebrolysin is soluble in water and commonly used solvents such as saline.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA as a medicinal product. Not a controlled substance.

🇦🇺AU

Not approved by the TGA as a medicinal product.

🇬🇧UK

Not approved by the MHRA as a medicinal product.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Community Insights

Publications per Year

49 total
1
00
1
01
1
02
1
09
1
10
3
12
1
13
1
14
3
15
2
16
3
17
5
19
2
20
2
21
4
22
11
23
4
24
3
25
Pricing

Price Comparison

  • BESTReceptor ChemUK
    60mg
    $38.09
    Price/mg
    $0.63/mg
    View
  • Double R LabsUS
    60mg
    $39.99
    Price/mg
    $0.67/mg
    View
  • RCpeptidesEU
    60mg
    $81.00
    Price/mg
    $1.35/mg
    View
  • Oasis LabsUS
    60mg
    $106.00
    Price/mg
    $1.77/mg
    View
  • Iron PeptidesUS
    60mg
    $109.99
    Price/mg
    $1.83/mg
    View

Top 5 of 7 offers from 7 vendors. Prices updated daily.

See all Cerebrolysin prices
Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for Cerebrolysin

Serum Level Visualizer

Visualize Cerebrolysin serum levels over time

Mechanism

Related Peptides

SelankCortagenDSIPN-Acetyl Semax AmidateDihexaPinealon

Track Cerebrolysin in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp StoreGet it onGoogle Play
Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer